Startup Showcase: Jinfiniti: What do you think?

Comprehensive biomarker tech: Invest, buy, or both? It’s time to have your say on Jinfiniti.

We like what Jinfiniti are doing; but that’s just our opinion – you’re the ones with the buying power and the investment potential: What do you think?

  • Watch the video pitch and investor questions;
  • Check-out the slide deck;
  • Take the 30 secs survey and see what others think!

The video pitch and investor questions:


The slide deck:

Jinfiniti Pich Deck Longevity.Technology


The 30-second survey (with live results):


Would you like to know more?

We’re happy to pass along your comments and questions to the Jinfiniti team: you can email us via this link. Thanks.


 

Thanks for engaging – we have regular Startup Showcases coming-up: stay tuned!

Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of Crowd Longevity a digital investment platform for international investors and Longevity start-ups launching in 2020.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Latest articles

Epigenetic regulation of protein homeostasis following DNA damage

Recent study identifies critical regulator of protein biosynthesis recovery and homeostasis required for Longevity. Unresolved DNA damage caused by intrinsic and environmental factors accumulates during...

Deep Longevity and Longenesis collaborate to clock aging

Start the clock to stop the clock – centralised data will aid Longevity research.  Deep Longevity, which engages in the development of explainable AI systems...

Big Brother approach to accelerate preclinical studies

Tracked.bio develops AI computer vision system that tracks flies and mice to reduce man-hours and increase data collected in Longevity studies. A Danish start-up aims...

Astellas to acquire iota Biosciences

Following an R&D collaboration that began last year, Japanese pharma Astellas has announced it will acquire bioelectronics firm iota in $304m deal. Last year's R&D...